The FDA expanded its import alert program to cover 38 additional foreign manufacturers of peptide APIs, the agency confirmed on May 29. The action represents the most aggressive enforcement posture the FDA has taken against overseas peptide ingredient sourcing, already triggering supply chain disruptions for US compounders and clinics.
Source: PeptideStaff
Import Alert 66-40 now flags manufacturers in China, India, and South Korea responsible for an estimated 30% of the injectable peptide API supply entering the US market annually. The largest concentration — 22 facilities — is based in China's Zhejiang and Jiangsu provinces. Facilities on the alert are subject to automatic detention at the border without physical examination.
The action follows a 14-month investigation triggered by adverse events linked to compounded injectable peptides. Inspectors found recurring deficiencies in sterility assurance, heavy metal contamination testing, and falsified Certificate of Analysis records at multiple overseas facilities.
The import alert is accelerating reshoring of peptide API sourcing. Several US-based peptide API manufacturers have reported surging inquiry volumes. Industry analysts estimate qualifying a new domestic API supplier takes 4–8 months under current FDA inspection timelines.